Table 2.

Basic data (mean ± SD or percentage) of patients in the second study

Variable	Actimel group	Yakult group	P value
n	30	30
Age (yr)	69.7 ± 17.6	74.1 ± 17.5	NS
Male gender	63.3%	60.0%	NS
PST 0 or 1	70.0%	51.7%	NS
BMI	25.9 ± 4.2	25.1 ± 4.1	NS
Creatinine (mg/dL)	1.2 ± 0.5	1.1 ± 0.3	NS
Albumin (mg/dL)	3.4 ± 0.3	3.3 ± 0.3	NS
Diagnosis (aite of infection/aepsis)	Pulmonary: 30.0% Genitourinary: 50.0% Biliary: 3.3% Sepsis: 0.0% Diverticulitis: 0.0% Dermal: 13.3% Misc.: 3.3%	Pulmonary: 50.0% Genitourinary: 26.7% Biliary: 6.7% Sepsis: 3.3% Diverticulitis: 3.3% Dermal: 6.7% Misc.: 3.3%	NS
Antibiotics	Ampicillin: 20.0% Cefuroxime: 20.0% Ceftriaxone: 20.0% Ciprofloxacin: 0.0% Clarithromycin: 10.0% Tazobactam: 0.0% Levofloxacin: 20.0% Moxifloxacin: 0.0% Cotrimoxazole: 3.3% Penicillin: 13.3%	Ampicillin: 36.7% Cefuroxime: 10.0% Ceftriaxone: 10.0% Ciprofloxacin: 3.3% Clarithromycin:16.7% Tazobactam: 10.0% Levofloxacin: 20.0% Moxifloxacin: 3.3% Cotrimoxazole: 6.7% Penicillin: 0.0%	NS
Days of treatment	6.0 ± 3.1	6.6 ± 3.7	NS
Concurrent PPI treatment	23.3%	50.0%	0.06
Antibiotic treatment in history	3.3%	10.0%	NS

NS: No significance; BMI: Body mass index.